Evidence map›Paper›PMID 35434579›Full record

ArticleEClinicalMedicine2022

Tobacco smoking changes during the first pre-vaccination phases of the COVID-19 pandemic: A systematic review and meta-analysis.

Peter Sarich, Citadel J Cabasag, Erica Liebermann, Pavla Vaneckova, Chelsea Carle, Suzanne Hughes, Sam Egger, Dianne L O'Connell, Marianne F Weber, Allini Mafra da Costa and 6 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Peter SarichThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Citadel J CabasagCancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Erica LiebermannCollege of Nursing, University of Rhode Island, RI, United States.
Pavla VaneckovaThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Chelsea CarleThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Suzanne HughesThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Sam EggerThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Dianne L O'ConnellThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Marianne F WeberThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Allini Mafra da CostaCancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Michael CaruanaThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Freddie BrayCancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Karen CanfellThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Ophira GinsburgCenter for Global Health, National Cancer Institute, MD, United States.
Julia SteinbergThe Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
Isabelle SoerjomataramCancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background: Globally, tobacco smoking remains the largest preventable cause of premature death. The COVID-19 pandemic has forced nations to take unprecedented measures, including 'lockdowns' that might impact tobacco smoking behaviour. We performed a systematic review and meta-analyses to assess smoking behaviour changes during the early pre-vaccination phases of the COVID-19 pandemic in 2020. Methods: We searched Medline/Embase/PsycINFO/BioRxiv/MedRxiv/SSRN databases (January-November 2020) for published and pre-print articles that reported specific smoking behaviour changes or intentions after the onset of the COVID-19 pandemic. We used random-effects models to pool prevalence ratios comparing the prevalence of smoking during and before the pandemic, and the prevalence of smoking behaviour changes during the pandemic. The PROSPERO registration number for this systematic review was CRD42020206383. Findings: 31 studies were included in meta-analyses, with smoking data for 269,164 participants across 24 countries. The proportion of people smoking during the pandemic was lower than that before, with a pooled prevalence ratio of 0·87 (95%CI:0·79-0·97). Among people who smoke, 21% (95%CI:14-30%) smoked less, 27% (95%CI:22-32%) smoked more, 50% (95%CI:41%-58%) had unchanged smoking and 4% (95%CI:1-9%) reported quitting smoking. Among people who did not smoke, 2% (95%CI:1-3%) started smoking during the pandemic. Heterogeneity was high in all meta-analyses and so the pooled estimates should be interpreted with caution ( Interpretation: Smoking behaviour changes during the first phases of the COVID-19 pandemic in 2020 were highly mixed. Meta-analyses indicated that there was a relative reduction in overall smoking prevalence during the pandemic, while similar proportions of people who smoke smoked more or smoked less, although heterogeneity was high. Implementation of evidence-based tobacco control policies and programs, including tobacco cessation services, have an important role in ensuring that the COVID-19 pandemic does not exacerbate the smoking pandemic and associated adverse health outcomes. Funding: No specific funding was received for this study.

Indexed as

CoronavirusCOVID-19SmokingSystematic reviewTobacco

Identifiers

PMID35434579
PMCPMC9002019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.